1.
|
Efficient Production of High Specific Activity Thulium-167 at Paul Scherrer Institute and CERN-MEDICIS
/ Heinke, Reinhard (CERN ; Leuven U.) ; Chevallay, Eric (CERN) ; Chrysalidis, Katerina (CERN) ; Cocolios, Thomas E (Leuven U.) ; Duchemin, Charlotte (Leuven U. ; CERN) ; Fedosseev, Valentin N (CERN) ; Hurier, Sophie (Leuven U. ; SCK-CEN, Mol) ; Lambert, Laura (CERN) ; Leenders, Benji (Leuven U. ; SCK-CEN, Mol ; Gent U.) ; Marsh, Bruce A (CERN) et al.
Thulium-167 is a promising radionuclide for nuclear medicine applications with potential use for both diagnosis and therapy (“theragnostics”) in disseminated tumor cells and small metastases, due to suitable gamma-line as well as conversion/Auger electron energies. However, adequate delivery methods are yet to be developed and accompanying radiobiological effects to be investigated, demanding the availability of $^{167}$Tm in appropriate activities and quality. [...]
2021
- Published in : Frontiers in Medicine 8 (2021) 712374
Fulltext: PDF;
|
|
2.
|
|
3.
|
CERN-MEDICIS: A Review Since Commissioning in 2017
/ MEDICIS Collaboration
The CERN-MEDICIS (MEDical Isotopes Collected from ISolde) facility has delivered its first radioactive ion beam at CERN (Switzerland) in December 2017 to support the research and development in nuclear medicine using non-conventional radionuclides. Since then, fourteen institutes, including CERN, have joined the collaboration to drive the scientific program of this unique installation and evaluate the needs of the community to improve the research in imaging, diagnostics, radiation therapy and personalized medicine. [...]
2021 - 11 p.
- Published in : Frontiers in Medicine 8 (2021) 693682
Fulltext: PDF;
|
|
4.
|
CERN-MEDICIS: A Unique Facility for the Production of Non-Conventional Radionuclides for the Medical Research
/ Duchemin, Charlotte (CERN) ; Barbero-Soto, Esther (CERN) ; Bernardes, Ana (CERN) ; Catherall, Richard (CERN) ; Chevallay, Eric (CERN) ; Cocolios, Thomas (Leuven U.) ; Dorsival, Alexandre (CERN) ; Fedosseev, Valentin (CERN) ; Fernier, Pascal (CERN) ; Gilardoni, Simone (CERN) et al.
The MEDICIS facility is a unique facility located at CERN dedicated to the production of non-conventional radionuclides for research and development in imaging, diagnostics and radiation therapy. It exploits in a Class A work sector, a dedicated isotope separator beam line, a target irradiation station at the 1.4 GeV Proton Synchroton Booster (PSB) and receives activated targets from external institutes during CERN Long Shut-Downs. [...]
CERN-ACC-2021-010.-
2021 - 5 p.
- Published in : JACoW IPAC 2020 (2020) THVIR13
Fulltext: PDF;
In : 11th International Particle Accelerator Conference, Caen, France, 10 - 15 May 2020, pp.THVIR13
|
|
5.
|
Exploring the Potential of High-Molar-Activity Samarium-153 for Targeted Radionuclide Therapy with [$^{153}$Sm]Sm-DOTA-TATE
/ Vermeulen, Koen (SCK-CEN, Mol) ; Van de Voorde, Michiel (SCK-CEN, Mol) ; Segers, Charlotte (SCK-CEN, Mol) ; Coolkens, Amelie (SCK-CEN, Mol) ; Pérez, Sunay Rodriguez (SCK-CEN, Mol) ; Daems, Noami (SCK-CEN, Mol) ; Duchemin, Charlotte (Leuven U. ; CERN) ; Crabbé, Melissa (SCK-CEN, Mol) ; Opsomer, Tomas (SCK-CEN, Mol) ; Vargas, Clarita Saldarriaga (SCK-CEN, Mol) et al.
Samarium-153 is a promising theranostic radionuclide, but low molar activities (Am) resulting from its current production route render it unsuitable for targeted radionuclide therapy (TRNT). Recent efforts combining neutron activation of $^{152}$Sm in the SCK CEN BR2 reactor with mass separation at CERN/MEDICIS yielded high-Am $^{153}$Sm. [...]
2022 - 15 p.
- Published in : Pharmaceutics 14 (2022) 2566
Fulltext: PDF;
|
|
6.
|
Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy
/ Van de Voorde, Michiel (SCK-CEN, Mol) ; Duchemin, Charlotte (Leuven U. ; CERN) ; Heinke, Reinhard (Leuven U. ; CERN) ; Lambert, Laura (CERN) ; Chevallay, Eric (CERN) ; Schneider, Thomas (CERN) ; Van Stenis, Miranda (CERN) ; Cocolios, Thomas Elias (Leuven U.) ; Cardinaels, Thomas (SCK-CEN, Mol ; Leuven U.) ; Ponsard, Bernard (SCK-CEN, Mol) et al.
Samarium-153 ($^{153}$Sm) is a highly interesting radionuclide within the field of targeted radionuclide therapy because of its favorable decay characteristics. $^{153}$Sm has a half-life of 1.93 d and decays into a stable daughter nuclide ($^{153}$Eu) whereupon β − particles [E = 705 keV (30%), 635 keV (50%)] are emitted which are suitable for therapy. [...]
2021 - 9 p.
- Published in : Frontiers in Medicine 8 (2021) 675221
Fulltext: PDF;
|
|
7.
|
Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations
/ Talip, Zeynep (PSI, Villigen) ; Borgna, Francesca (PSI, Villigen) ; Müller, Cristina (PSI, Villigen ; ETH, Zurich (main)) ; Ulrich, Jiri (PSI, Villigen) ; Duchemin, Charlotte (CERN ; Leuven U.) ; Ramos, Joao P (CERN ; Leuven U.) ; Stora, Thierry (CERN) ; Köster, Ulli (Laue-Langevin Inst.) ; Nedjadi, Youcef (Lausanne U.) ; Gadelshin, Vadim (CERN ; Mainz U., Inst. Phys. ; Urals State U.) et al.
The $\beta^-$-particle-emitting erbium-169 is a potential radionuclide toward therapy of
metastasized cancer diseases. It can be produced in nuclear research reactors,
irradiating isotopically-enriched $^{168}$Er$_2$O$_3$ [...]
2021 - 11 p.
- Published in : Frontiers in Medicine 8 (2021) 643175
Fulltext: PDF;
|
|
8.
|
Polonium evaporation from dilute liquid metal solutions
/ Rizzi, Matthias (PSI, Villigen ; U. Bern (main)) ; Neuhausen, Jörg (PSI, Villigen) ; Eichler, Robert (PSI, Villigen ; U. Bern (main)) ; Türler, Andreas (PSI, Villigen ; U. Bern (main)) ; Mendonça, Tania Melo (CERN) ; Stora, Thierry (CERN) ; Gonzalez Prieto, Borja (SCK-CEN, Mol ; KU Leuven) ; Aerts, Alexander (SCK-CEN, Mol) ; Schumann, Dorothea (PSI, Villigen)
The evaporation behavior of polonium as one of the most hazardous radionuclides produced in spallation based neutron sources with liquid lead-bismuth targets has been quantified in this study. The normalized apparent vapor pressure, i.e. [...]
2014
- Published in : J. Nucl. Mater. 450 (2014) 304-313
|
|
9.
|
Resonant laser ionization and mass separation of $^{225}$Ac
/ Johnson, Jake D (Leuven U.) ; Heines, Michael (Leuven U.) ; Bruchertseifer, Frank (Geel, JRC) ; Chevallay, Eric (CERN) ; Cocolios, Thomas E (Leuven U.) ; Dockx, Kristof (Leuven U.) ; Duchemin, Charlotte (Leuven U. ; CERN) ; Heinitz, Stephan (SCK-CEN, Mol) ; Heinke, Reinhard (Leuven U. ; CERN) ; Hurier, Sophie (Leuven U. ; SCK-CEN, Mol) et al.
$^{225}$Ac is a radio-isotope that can be linked to biological vector molecules to treat certain distributed cancers using targeted alpha therapy. However, developing $^{225}$Ac-labelled radiopharmaceuticals remains a challenge due to the supply shortage of pure $^{225}$Ac itself. [...]
2023 - 11 p.
- Published in : Sci. Rep. 13 (2023) 1347
Fulltext: PDF;
|
|
10.
|
CERN-MEDICIS: Operational indicators to support the production of new medical radionuclides by mass-separation
/ Stora, T (CERN) ; Duchemin, C (CERN) ; Andreazza, W (CERN) ; Aubert, E (CERN) ; Bernerd, C (CERN ; Leuven U.) ; Cocolios, T (Leuven U.) ; Deschamps, M (CERN) ; Dorsival, A (CERN) ; Duraffourg, M (CERN) ; Fedosseev, V (CERN) et al.
CERN-MEDICIS is an isotope mass separation facility for biomedical R&D; located in a class A laboratory, receiving up to 50% of the 1.4GeV PSB protons. It was commissioned with radioactive ion beams in 2017. [...]
2023 - 6 p.
- Published in : J. Phys. : Conf. Ser.: 2687 (2024) , no. 8, pp. 082039
- Published in : JACoW IPAC: 2023 (2023) , pp. WEPM125
Fulltext: PublicationJACoW - PDF; PublicationIOP - PDF;
In : 14th International Particle Accelerator Conference (IPAC 2023), Venice, Italy, 7 - 12 May 2023, pp.082039
|
|